FDA Planning More Inspections Of Gene Therapy Trials During IND Phase
Executive Summary
FDA plans to step up inspections of gene therapy trials while they are in the IND phase, FDA Office of Therapeutics Research & Review Director Jay Siegel, MD, told the Senate Health/Public Health Subcommittee during a Feb. 2 hearing on gene therapy.
You may also be interested in...
FDA Inspecting All NME Applications For Appropriate Clinical Trial Monitoring
FDA's Division of Scientific Investigation has expanded its inspection efforts to examine all new molecular entity applications for appropriate clinical trial monitoring.
FDA Inspecting All NME Applications For Appropriate Clinical Trial Monitoring
FDA's Division of Scientific Investigation has expanded its inspection efforts to examine all new molecular entity applications for appropriate clinical trial monitoring.
Targeted Genetics Inherits Biogen & Genzyme Alliances In Genovo Acquisition
Targeted Genetics will inherit partnerships with Biogen and Genzyme when it completes the acquisition of Genovo, according to an Aug. 9 merger agreement.